©1996 by The American Society for Biochemistry and Molecular Biology, Inc.
Exchange of - for -Tropomyosin in Hearts of Transgenic Mice Induces Changes in Thin Filament Response to Ca, Strong Cross-bridge Binding, and Protein Phosphorylation (*)

(Received for publication, February 1, 1996; and in revised form, March 26, 1996)

Kimberly A. Palmiter (1) Yoshimi Kitada (1) Mariappan Muthuchamy (2) David F. Wieczorek (2) R. John Solaro (1)(§)

From the  (1)Department of Physiology and Biophysics, University of Illinois, College of Medicine, Chicago, Illinois 60612 and the (2)Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati, College of Medicine, Cincinnati, Ohio 45267

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

Despite its potential as a key determinant of the functional state of striated muscle, the impact of tropomyosin (Tm) isoform switching on mammalian myofilament activation and regulation in the intact lattice remains unclear. Using a transgenic approach to specifically exchange beta-Tm for the native alpha-Tm in mouse hearts, we have been able to uncover novel functions of Tm isoform switching in the heart. The myofilaments containing beta-Tm demonstrated an increase in the activation of the thin filament by strongly bound cross-bridges, an increase in Ca sensitivity of steady state force, and a decrease in the rightward shift of the Ca-force relation induced by cAMP-dependent phosphorylation. Our results are the first to demonstrate the specific effects of Tm isoform switching on mammalian thin filament activation in the intact lattice and suggest an important role for Tm in modulation of myofilament activity by phosphorylation of troponin.


INTRODUCTION

The ability of myosin heads to react with actin in heart muscle occurs with a transition of the thin filament from an ``off'' to an ``on'' state that depends on complex alterations involving the tropomyosin (Tm) (^1)molecule (for reviews see (1) and (2) ). These alterations include possible steric effects associated with changes in the position of Tm on the thin filament, as well as allosteric and cooperative effects associated with Tm-induced changes in actin structure and reactivity with myosin(3, 4, 5) . The steric and allosteric/cooperative alterations involving Tm are triggered by Ca binding to TnC, but also depend on myosin head binding(6) . Ca binding to TnC promotes interactions with other Tn components, TnI(2) , an inhibitory protein that binds to actin, as well as TnT, a TnI- and Tm-binding protein. The steric model of activation (3) hypothesizes that Ca-TnC-induced movement of Tm or possibly TnI (2) reverses the off state by releasing actin sites for reaction with myosin. The allosteric model(4, 5) proposes that Ca-TnC itself cannot activate the thin filament, but acts as a co-factor shifting the equilibrium between off and on states of Tm such that strongly bound cross-bridges more easily activate the thin filament. Although recent considerations indicate that activation may involve both processes(2) , the relative role of the steric and allosteric/cooperative mechanisms in turning on the activity of striated muscle remains unclear.

Our perception of the role of Tm in the regulation of striated muscle, as well as it's structure/function relations, has come from a variety of approaches. These include x-ray diffraction of muscle preparations (7) and crystals(8, 9) , reconstructions from electron micrographs(9, 10) , and reconstitution studies of soluble systems with Tm(11, 12, 13) , Tm peptides(14) , and mutants of Tm(15) . In some cases, inferences regarding structure/function relations have been made from comparisons of muscle fibers containing isoforms of Tm(16) . However, interpretation of these studies is difficult in that there are multiple changes in myofilament proteins that occur along with the natural variations in Tm. A clearer understanding of the structure/function relations of Tm has been hampered by an apparent lack of methods for reversibly extracting Tm from the myofilament lattice in a force-generating system, as has proved so successful in the case of Tn components such as TnC and TnI(17) . Thus, issues such as the role of Tm domains, covalent modifications, and the functional significance of isoform switching of Tm in the intact force-generating lattice of vertebrate-striated muscle have remained poorly understood. Delineating the functional differences between Tm isoforms has taken on new significance with the identification of missense mutations in the Tm gene causally linked to familial hypertrophic cardiomyopathy (18, 19, 20) .

In the present experiments, we used a transgenic approach to overcome the difficulties of exchanging Tm isoforms in the intact myofilament lattice. Transgenic mice, which overexpress beta-Tm in the heart, were generated as described previously(21) . This has permitted us to test explicitly the effects of alterations in Tm isoforms on myofilament activation. Our results provide the first unambiguous evidence that myofilament activation by Ca and strong cross-bridges is affected by the population of Tm isoforms present in the heart. Our results also indicate a role for Tm in the modulation of myofilament activation by phosphorylation of Tn. Some of our results have been published in abstract form(22) .


EXPERIMENTAL PROCEDURES

Materials

ATP (from equine muscle), creatine phosphate, creatine phosphokinase, cAMP, EGTA, MOPS, saponin, and the protease inhibitors pepstatin A, leupeptin, and phenylmethylsulfonyl fluoride were purchased from Sigma. Calyculin A and Triton X-100 were purchased from Calbiochem-Novabiochem Corp. Alkaline phosphatase-conjugated goat-anti-mouse IgG (Fc), nitro blue tetrazolium, and 5-bromo-4-chloro-3-indolyl phosphate were purchased from Promega Corp. [P]ATP (3000 Ci/mmol) was obtained from DuPont NEN products. Kodak X-Omat scientific imaging film (Eastman Kodak Co.) was used for autoradiography and was purchased from Fisher.

Transgenic Animals

Transgenic mice (FVBN strain) were generated as described previously by Muthuchamy et al.(21) . Expression of the transgene was driven by the murine alpha-myosin heavy chain promoter which, as demonstrated previously(23) , restricts expression to the heart. The mice demonstrated no gross phenotypic abnormalities, no evidence of neonatal mortality, and no histological evidence of abnormalities or hypertrophy.

Gel Electrophoresis and Western Blotting

SDS-polyacrylamide gel electrophoresis was performed according to the method of Laemmli (24) . Myofibrils were isolated as described previously(25) , separated on a 12.5% SDS gel, and transferred to nitrocellulose paper according to the method of Towbin et al.(26) for Western blot analysis. Primary antibody incubations were performed with a 1:1000 dilution of CH1 antibody which recognizes both Tm isoforms. Secondary antibody incubations were performed with alkaline phosphatase conjugated goat-anti-mouse IgG. Color development occurred over a 5-min period using the nitro blue tetrazolium/5-bromo-4-chloro-3-indolyl phosphate system.

Fiber Bundle Preparation

Left ventricular trabeculae were excised from the heart and dissected into fiber bundles approximately 100-150 µm in width and 2-3.5 mm in length. Fibers were dissected and stored in a low relaxing solution containing 0.1 mM EGTA in standard buffer (20 mM MOPS at pH 7.0, 1 mM free Mg, 5 mM MgATP, 12 mM creatine phosphate) at pCa 9.0, pH 7.0 at 4 °C. Low relaxing solution also contained the protease inhibitors, pepstatin A (2.5 µg/ml), leupeptin (1 µg/ml), and phenylmethylsulfonyl fluoride (25 µM).

Force Measurements

Fiber bundles were mounted between a micromanipulator and a force transducer (27) with cellulose-acetate glue. Fibers were then extracted for 30 min at 22 °C in a 250 µg saponin/ml high relaxing solution (10 mM EGTA in standard buffer). After a maximal contraction at pCa 4.5, the fiber bundle was relaxed in high relaxing solution. The fiber bundles were then immersed in successive solutions of varying pCa or pMgATP. Following relaxation in high relaxing solution, a second pCa 4.5 contraction was performed to assess fiber viability. The ionic compositions of the solutions were computed by solving multiequilibria equations with the use of a computer program(28) .

Conditions for cAMP-dependent Phosphorylation

cAMP-dependent phosphorylation was induced by incubating detergent-extracted fiber bundles in a phosphorylation buffer containing 10 mM EGTA, 20 mM MOPS at pH 7.0, 1 mM free Mg, 2 mM MgATP, 12 mM creatine phosphate, 80 µCi/ml [P]ATP, and 100 µM cAMP. The protocol used to phosphorylate myofilaments in detergent-extracted preparations was modified after that described by Herzig et al.(29) , who demonstrated full phosphorylation of cardiac skinned fiber bundles by endogenous PKA and 100 µM cAMP after 10-20 min of incubation. Even so, to ensure full phosphorylation of TnI in both NTG and TG-beta-Tm fiber bundles, the preparations were incubated for 30 min with cAMP in the presence of calyculin A (100 ng/ml), a phosphatase inhibitor. In some experiments, exogenous PKA (10 µg/ml) was also added to the incubation solution, giving the same results as in the absence of added PKA. To remove excess [P]ATP and to stop the reaction, myofilaments were washed three times with ice-cold phosphorylation buffer. The fibers were then solubilized in 130 mM Tris-HCl, pH 6.8, and total protein was determined by the method of Lowry et al.(30) . Equivalent amounts of protein were loaded onto SDS gels. Gels were exposed to Kodak X-Omat scientific imaging film for 24 h at -80 °C and then developed.

Calculations and Statistics

Individual pMgATP- or pCa-force determinations were normalized to a maximum generated specifically for each measurement by Graphpad Inplot curve fitting software, Graphpad Software Inc. The normalized values where then grouped and averaged and used for calculation of the final curves as illustrated in Fig. 2and Fig. 3. Statistical calculations were made using Sigmastat software, Jandel Corp. Values were considered significantly different if p < 0.05 as determined by two-way ANOVA.


Figure 2: The relation between pMgATP and force of NTG and TG-beta-Tm fiber preparations. Detergent-extracted fiber preparations were sequentially exposed to solutions of decreasing MgATP concentration at pCa 9.0. In both cases, the peak force obtained at pMgATP 5.4 in the NTG fibers and pMgATP 5.0 in the TG-beta-Tm fibers was only approximately half that obtained under maximal Ca-activated conditions at pCa 4.5 (data not shown). Values are expressed as the mean ± S.E. of n = 5 from 3 different hearts. *, p < 0.05 as determined by Student Newman Keul's post hoc t-test. bullet, NTG; , TG-beta-Tm.




Figure 3: The effect of cAMP-dependent phosphorylation on the pCa and force relation in NTG and TG-beta-Tm fiber preparations. A, pCa-force relation of detergent-extracted NTG (bullet, circle) and TG-beta-Tm (, up triangle) fiber preparations under control conditions (A, bullet, ) and under phosphorylating conditions (B, circle, up triangle). Inset, protein phosphorylation profile of detergent-extracted NTG and TG-beta-Tm myofilament preparations performed as described under ``Experimental Procedures.'' All phosphorylation experiments represent at least 3 individual determinations. Values are expressed as the mean ± S.E. In the case of the NTG preparations, n = 3 from 3 different hearts. In the case of the TG preparations, n = 5 from 3 different hearts. Each individual determination involved sequentially immersing a fiber in two sets of solutions of varying pCa values. The first set of Ca solutions to which a fiber was exposed (under control conditions) had no added cAMP. After obtaining the initial measurements, the fiber bundle was then incubated under phosphorylating conditions (see text and ``Experimental Procedures'') and then reimmersed in solutions of varying pCa in the presence of 100 µM cAMP.




RESULTS

Fig. 1A illustrates the SDS-PAGE protein profiles of detergent-treated myofilament preparations from NTG and TG-beta-Tm mouse hearts (lanes 1 and 2, respectively). Tm was identified in the two preparations by Western blot analysis as illustrated in Fig. 1B (NTG, lane 1, and TG-beta-Tm, lane 2). This analysis demonstrated that NTG hearts express only alpha-Tm in the myofilaments, whereas beta-Tm is abundantly expressed in myofilaments from TG-beta-Tm hearts. We found no changes in the expression of other myofilament proteins. The results illustrated in Fig. 1show that our transgenic approach has made experiments explicitly testing the effects of alterations in Tm isoforms on myofilament activation possible.


Figure 1: SDS-PAGE and Western blot analysis of NTG and TG-beta-Tm cardiac myofibrillar preparations. A, 12.5% SDS-polyacrylamide gel onto which 50 µg of total cardiac myofibrillar protein from NTG (lane 1) and TG-beta-Tm (lane 2) samples was loaded. B, Western blot performed with a monoclonal antibody which recognizes both Tm isoforms and done specifically to identify the type(s) of Tm present in the myofilaments (NTG, lane 1, and TG-beta-Tm, lane 2). Our results clearly demonstrate that NTG preparations contain only alpha-Tm whereas TG-beta-Tm preparations contain an abundance of beta-Tm.



As a method for probing the effects of Tm isoform switching on the cooperative activation of the thin filament, we controlled the population of strongly bound cross-bridges by varying the MgATP concentration at pCa 9.0 in detergent-treated fiber bundles (Fig. 2) from nontransgenic and transgenic preparations. At relatively high concentrations of MgATP, force was low reflecting relaxing conditions and a high population of cross-bridges with bound nucleotide. As the MgATP concentration was lowered, force increased, even at pCa 9.0, as strongly bound rigor cross-bridges (nucleotide-free) activated the thin filament. Maximum force was a function of the number of cycling and rigor cross-bridges as well as the relative activation of the thin filament. As illustrated in Fig. 2, at pMgATP 5.0, myofilaments containing beta-Tm developed significantly more force than myofilaments containing only alpha-Tm. Assuming that the number of rigor cross-bridges is the same in both preparations, our results indicate that Tm isoform switching increased the ability of strong cross-bridge binding to activate the thin filament.

Myofilament activation via Ca binding to TnC was also measured in skinned fiber preparations. Results presented in Fig. 3A indicate that the force developed by TG-beta-Tm myofilaments was significantly (p leq 0.05 two-way ANOVA) more sensitive to Ca than NTG myofilaments. The pCa was 5.72 ± 0.01 for TG-beta-Tm preparations and 5.57 ± 0.04 for NTG preparations.

A unique property of cardiac TnI that may be important in its reaction with Tm is that it is phosphorylated by PKA(31) . In experiments reported in Fig. 3, we compared the pCa-force relations for NTG and TG-beta-Tm fiber bundles before and after phosphorylation by cAMP/PKA as described under ``Experimental Procedures.'' Our results show that the difference in Ca sensitivity between NTG and TG-beta-Tm myofilaments was even more pronounced when the myofilaments were phosphorylated by PKA (Fig. 3B). As expected from previous experiments(32) , the NTG myofilaments responded to cAMP-dependent phosphorylation of TnI by a rightward shift of the pCa-force relation. Yet, in TG-beta-Tm myofilaments, there was no significant rightward shift of the pCa-force relation with cAMP-dependent phosphorylation. This resulted in a significant (p < 0.05, two-way ANOVA) magnification of the differences in pCa between NTG (5.46 ± 0.018) and TG-beta-Tm (5.69 ± 0.01) myofilaments. Levels of TnI phosphorylation in NTG and TG-beta-Tm preparations are illustrated by the data shown in the inset of Fig. 3. The ratio of autoradiogram band intensity to TnI staining was 3.56 for NTG preparations and 3.78 for TG-beta-Tm preparations. Based on these results, we conclude that the stoichiometry of TnI phosphorylation was the same in each case. These data are the first to demonstrate, in the intact myofilament lattice, a role for Tm isoform switching in the desensitization of myofilaments by phosphorylation of TnI.


DISCUSSION

Our data provide the first clear evidence that exchange of beta-Tm for alpha-Tm alters thin filament activation by cross-bridge binding. It is known that strong binding of cross-bridges is able to ``turn-on'' many actins through a cooperative process that requires Tm(6) . Moreover, when overlap between adjacent Tm molecules is removed, cooperative cross-bridge-actin binding is significantly reduced(33) . In the mouse, isoform switching from alpha- to beta-Tm involves 39 amino acid substitutions. Twenty five of these substitutions occur in the C-terminal half of the molecule, (^2)a region important for Tm head-to-tail interactions. Previous studies (21) have demonstrated the preferential formation of alphabeta-Tm heterodimers in these transgenic cardiac myofilaments. This does not, however, preclude the formation of betabeta-Tm homdimers which were undoubtedly present due to the abundance of beta-Tm expressed. Importantly, Thomas and Smillie (13) have reported that betabeta-Tm has a greater propensity to form end-to-end interactions than either alphabeta- or alphaalpha-Tm, which may significantly alter the cooperative potential of the myofilaments containing beta-Tm. Additionally, amino acid substitutions Ser Glu and His Asn result in beta-Tm having a(-2) charge change relative to alpha-Tm.^2 These changes could affect cooperative activation of thin filaments: (i) by altering the interaction of Tm with the seven actins under its control or (ii) by affecting end-to-end interactions linking near neighbor functional units consisting of actin-Tm-Tn in a 7:1:1 ratio.

Based on previous studies, it is not surprising that isoform switching from alpha-Tm to beta-Tm alters thin filament activation by Ca. Ca binding activates the thin filament by altering the interactions of TnC with TnT (34) and TnI(35, 36) . These changes induce changes in the binding of Tm to actin (10) and promote cross-bridge binding to actin. Importantly, TnT has been shown to bind more weakly to beta-Tm than to alpha-Tm(37) . Thus, it would be expected that activation may occur at a lower level of free Ca in myofilaments containing beta-Tm.

Our results also implicate a role for Tm isoform switching in the modulation of thin filament activation by phosphorylation of TnI. Although the inhibitory activity of TnI is potentiated by Tm(6) , how phosphorylation of TnI might alter its interaction with Tm has not been appreciated. In vitro studies of Al-Hillawi et al.(38) demonstrated that cooperative binding of TnI to actin-Tm is abolished when TnI is phosphorylated. Our hypothesis is that isoform switching from alpha-Tm to beta-Tm itself results in a weaker cooperative interaction between TnI, actin, and Tm. Thus, the effect of TnI phosphorylation may be minimized or lost in myofilaments containing beta-Tm.

An increased Ca sensitivity and a reduced effect of TnI phosphorylation on myofilaments containing beta-Tm serves to explain results of studies on isolated working hearts from NTG and TG-beta-Tm mice. Muthuchamy et al.(21) showed that, compared to controls, TG-beta-Tm working heart preparations demonstrated an increase in the time for half-maximal relaxation of ventricular pressure. This fits with our findings of increased Ca sensitivity in myofilaments containing beta-Tm. Moreover, the difference in half-maximal relaxation time was increased with low level beta-adrenergic stimulation. This is what we would expect given that beta-adrenergic stimulation, which results in TnI phosphorylation, has been shown to reduce myofilament Ca sensitivity, thereby enhancing relaxation(39) . Our results on skinned fiber bundles indicate that this relaxant effect, associated with TnI phosphorylation, would be much reduced or absent in the TG heart.

Our results also have important implications regarding the etiology of FHC, which is genetically linked to sarcomeric mutations (for review, see (40) ) Two of the three point mutations found in the alpha-Tm gene of patients with FHC involve charge changes in the putative Ca-dependent TnT binding domain(18, 19, 20) . Our data show that isoform switching involving charge changes near this domain enhance myofilament Ca sensitivity, an effect expected to slow relaxation as demonstrated in working heart preparations(21) . Interestingly, point mutations in myosin heavy chain linked to FHC also slow contraction dynamics(41, 42) . Thus, the mechanism for the slowing need not involve myosin, but could occur through changes in myofilament response to Ca exacerbated during exercise. The ability to test these ideas in transgenic animals brings us closer to understanding the functional differences between Tm isoform populations in physiological and pathological settings.


FOOTNOTES

*
This work was supported by National Institutes of Health Grants HL 22231 (to R. J. S.), T32 HL-07692 (to K. A. P.), and HL 46826 (to D. F. W.), and American Heart Association, Ohio Affiliate Grant SW-93-36-F (to M. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept. of Physiology and Biophysics (M/C 901), College of Medicine, University of Illinois, 835 S. Wolcott Ave., Chicago, IL 60612-7342. Tel.: 312-996-7620; Fax: 312-996-1414.

(^1)
The abbreviations used are: Tm, tropomyosin; Tn, troponin; FHC, familial hypertrophic cardiomyopathy; MOPS, 3-(N-morpholino)propanesulfonic acid; PAGE, polyacrylamide gel electrohoresis; PKA, protein kinase A; pCa, -log of half-maximal molar Ca; pMgATP, -log molar MgATP; NTG, nontransgenic; TG-beta-Tm, transgenic mouse myofilaments containing beta-Tm; PKA, protein kinase A; ANOVA, analysis of variance.

(^2)
M. Muthuchamy and D. F. Wieczorek, manuscript in preparation.


ACKNOWLEDGEMENTS

We thank Mary D. Johnson for expert technical assistance.


REFERENCES

  1. Solaro, R. J., and Van Eyk, J. E. (1996) J. Mol. Cell. Cardiol. 28, 217-230 [CrossRef][Medline] [Order article via Infotrieve]
  2. Lehrer, S. S. (1994) J Muscle Res. Cell Motil. 15, 232-236 [Medline] [Order article via Infotrieve]
  3. Huxley, H. E. (1973) Cold Spring Harbor Symp. Quant. Biol. 37, 361-376
  4. Hill, T. L., Eisenberg, E., and Greene, L. (1980) Proc. Natl. Acad. Sci. U. S. A. 77, 3186-3190 [Abstract]
  5. McKillop, D. F. A., and Geeves, M. A. (1993) Biophys. J. 65, 693-701 [Abstract]
  6. Bremel, R. D., Murray, J. M., and Weber, A. M. (1972) Cold Spring Harbor Symp. Quant. Biol. 37, 267-275
  7. Popp, D., and Maeda, Y. (1993) J. Mol. Biol. 229, 279-285 [CrossRef][Medline] [Order article via Infotrieve]
  8. O'Brien, E. J., Gillis, J. M., and Couch, J. (1975) J. Mol. Biol. 99, 461-475 [Medline] [Order article via Infotrieve]
  9. Phillips, G. N., Jr., Fillers, J. P., and Cohen, C. (1986) J. Mol. Biol. 192, 111-131 [Medline] [Order article via Infotrieve]
  10. Lehman, W., Craig, R., and Vilbert, P. (1994) Nature 368, 65-67 [CrossRef][Medline] [Order article via Infotrieve]
  11. Chalovich, J. M., and Eisenberg, E. (1982) J. Biol. Chem. 257, 2432-2437 [Free Full Text]
  12. Cummins, P., and Perry, S. V. (1973) Biochem. J. 133, 765-777 [Medline] [Order article via Infotrieve]
  13. Thomas, L. B., and Smillie, L. B. (1994) Biophys. J. 66, A310 [Abstract]
  14. Greenfield, N. J., Strafford, W. F., and Hitchcock-DeGregori, S. E. (1994) Protein Sci. 3, 402-410 [Abstract/Free Full Text]
  15. Cho, Y.-J., Liu, J., and Hitchcock-DeGregori, S. E. (1990) J. Biol. Chem. 265, 538-545 [Abstract/Free Full Text]
  16. Amphlett, G. W., Syska, H., and Perry, S. V. (1976) FEBS Lett. 63, 22-26 [CrossRef][Medline] [Order article via Infotrieve]
  17. Moss, R. L. (1992) Circ. Res. 70, 865-884 [Abstract]
  18. Theirfelder, L., Watkins, H., MacRae, C., Lamas, R., McKenna, W., Vosberg, H., Seidman, J. G., and Seidman, C. E. (1994) Cell 77, 701-712 [Medline] [Order article via Infotrieve]
  19. Nakajima-Taniguchi, C., Matsui, H., Nagata, S., Kishimoto, T., and Yamauchi-Takihara, J. (1995) J. Mol. Cell. Cardiol. 27, 2053-2058 [Medline] [Order article via Infotrieve]
  20. Watkins, H., McKenna, W. J., Theirfelder, L., Suk, H. J., Anan, R., O'Donoghue, A., Spirito, P., Matsumori, A., Moravec, C. S., Seidman, J. G., and Seidman, C. E. (1995) N. Engl. J. Med. 332, 1058-1064 [Abstract/Free Full Text]
  21. Muthuchamy, M., Grupp, I. L., Grupp, G., O'Toole, B. A., Kier, A. B., Boivin, G. P., Neumann, J., and Wieczorek, D. F. (1995) J. Biol. Chem. 270, 30593-30603 [Abstract/Free Full Text]
  22. Palmiter, K. A., Kitada, Y., Muthuchamy, M., Wieczorek, D., and Solaro, R. J. (1995) Biophys. J. 68, 57 (abstr.)
  23. Subramaniam, A., Jones, W. K., Gulick, J., Wert, S., Neumann, J., and Robbins, J. (1990) J. Biol. Chem. 266, 24613-24620 [Abstract/Free Full Text]
  24. Laemmli, U. K. (1970) Nature 227, 680-685 [Medline] [Order article via Infotrieve]
  25. Pagani, E. D., and Solaro, R. J. (1984) in Methods in Pharmacology (Schwartz, A., ed) pp. 44-61, Plenum Publishing Corp., New York
  26. Towbin, H., Staehelin, T., and Gordon, J. (1979) Proc. Natl. Acad. Sci. U. S. A. 76, 4350-4354 [Abstract]
  27. Chiu, Y., Asayama, J., and Ford, L. E. (1982) Am. J. Physiol. 243, C299-C302
  28. Godt, R. E., and Lindley, B. D. (1982) J. Gen. Physiol. 80, 279-297 [Abstract]
  29. Herzig, J. W., Kohler, G., Pfitzer, G., Ruegg, J. C., and Wolffle, G. (1981) Pfluegers Arch. Eur. J. Physiol. 391, 208-212 [Medline] [Order article via Infotrieve]
  30. Lowry, D. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) J. Biol. Chem. 193, 165-175
  31. Solaro, R. J., Moir, A. J. G., and Perry, S. V. (1976) Nature 262, 615-617 [Medline] [Order article via Infotrieve]
  32. Guo, X., Wattanapermpool, J., Palmiter, K. A., Murphy, A. M., and Solaro, R. J. (1994) J. Biol. Chem. 269, 15210-15216 [Abstract/Free Full Text]
  33. Pan, B.-S., Gordon, A. M., and Luo, Z. (1989) J. Biol. Chem. 264, 8495-8498 [Abstract/Free Full Text]
  34. Iio, T. (1985) J. Biochem. (Tokyo) 98, 261-263 [Abstract]
  35. Tao, T., Gong, B., and Leavis, P. C. (1990) Science 2, 1339-1341
  36. Strasburg, G. M., Leavis, P. C., and Gergely, J. (1985) J. Biol. Chem. 260, 366-370 [Abstract/Free Full Text]
  37. Pearlstone, J. R., and Smillie, L. B. (1982) J. Biol. Chem. 257, 10587-10592 [Abstract]
  38. Al-Hillawi, E., Bhandari, D. G., Trayer, H. R., and Trayer, I. P. (1995) Eur. J. Biochem. 228, 962-970 [Abstract]
  39. Zhang, R., Zhao, J., Mandiveno, A., and Potter, J. D. (1995) Circ. Res. 76, 1028-1035 [Abstract/Free Full Text]
  40. Durand, J.-B., Anchee, A. B., and Roberts, R. (1995) Ann. Med. 27, 311-317 [Medline] [Order article via Infotrieve]
  41. Sweeny, H. L., Straceski, A. J., Leinwand, L. A., Tukunor, B. A., and Faust, L. (1994) J. Biol. Chem. 269, 1603-1605 [Abstract/Free Full Text]
  42. Cuda, G., Fananapazir, L., Zhu, W., Sellers, J. R., and Epstein, N. D. (1993) J. Clin. Invest. 91, 2861-2865 [Medline] [Order article via Infotrieve]

©1996 by The American Society for Biochemistry and Molecular Biology, Inc.